Dignify Therapeutics

CompanyUnited States

Dignify Therapeutics develops one asset, in phase 1 (DTI-117 in neurogenic bowel dysfunction). Mostly other; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1
  • DTI-117

    Phase 1, Other, neurogenic bowel dysfunction

Full company profiles: pipeline, trials, funding and people.

See Pro

Intelligence